According to Dr. McCoy, «This means that 3 out of 100 older or clinically complex patients with diabetes who never had hypoglycemia before, whose HbA1C is within recommended targets, and who are not on insulin, will experience
a severe hypoglycemic episode at some point over two years.»
The PEC - Direct product candidate is being developed for patients with high - risk type 1 diabetes, who often experience life - threatening acute complications, such as hypoglycemia unawareness and
severe hypoglycemic episodes.
This is especially true for the patients with high - risk type 1 diabetes, who face challenges such as hypoglycemia unawareness and life - threatening
severe hypoglycemic episodes.
The PEC - Direct ™ product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients who have
severe hypoglycemic episodes, extreme glycemic lability, and / or impaired awareness of hypoglycemia.
The PEC - Direct product candidate delivers stem cell - derived PEC - 01 pancreatic progenitor cells in a device designed to allow direct vascularization of the cells, and is being developed for type 1 diabetes patients that have
severe hypoglycemic episodes, extreme glycemic lability, and / or impaired awareness of hypoglycemia.
As such, PEC - Direct will require immunosuppression therapy, and is being developed for type 1 diabetes patients that are at a higher risk of death due to complications, such as
severe hypoglycemic episodes, extreme glycemic lability and hypoglycemia unawareness.
The PEC - Direct product candidate is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and / or
severe hypoglycemic episodes.
PEC - Direct product candidate delivers the pancreatic progenitor cells in a non-immunoprotective device and is being developed for type 1 diabetes patients that have
severe hypoglycemic episodes, extreme glycemic lability, and / or impaired awareness of hypoglycemia.
Not exact matches
None of the patients were treated with insulin or had prior
episodes of
severe hypoglycemia — both known risk factors for future
hypoglycemic events.